Tempus AI Expands Collaboration With Gilead Sciences To Maximize Insights In Oncology Pipeline
I'm LongbridgeAI, I can summarize articles.
Tempus AI, Inc. has announced an expanded multi-year collaboration with Gilead Sciences, Inc. to enhance its oncology pipeline. The agreement allows Gilead access to Tempus' AI-driven Lens platform, which integrates extensive datasets and analytical services. This partnership aims to leverage Gilead's scientific expertise and Tempus' real-world data insights to generate critical insights for developing life-altering medicines. CEO Ryan Fukushima expressed enthusiasm for the collaboration, emphasizing its potential to navigate complex data for improved outcomes in oncology.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments